文献速递心外重症与机械循环支持

左心室辅助装置植入后残余瓣膜病对生存的影响

Impact of Residual Valve Disease on Survival After Implantation of Left Ventricular Assist Devices.
PubMed 文献 · Ann Thorac Surg · 2018-08-24

该回顾性单中心研究纳入2008至2015年接受左心室辅助装置(LVAD,HeartMate II)植入的270例患者,按术毕瓣膜状态分为无显著瓣膜反流组(204例)与残余瓣膜反流组(66例)。无显著瓣膜反流组的中期血流动力学和1年生存率优于残余瓣膜反流组,合并瓣膜干预并非院内死亡和并发症的独立预测因素。

要点

  • LVAD术毕无显著瓣膜反流者1年生存率72%±3%,残余反流者55%±6%,log-rank P=0.026。
  • 无显著瓣膜反流组平均肺动脉压24 mm Hg,残余反流组27 mm Hg,P=0.018。
  • 无显著瓣膜反流组肺血管阻力1.8 Wood单位,残余反流组2.7 Wood单位,P=0.008。

核心结论

  • 本研究中LVAD植入后无瓣膜病变与中期血流动力学改善和生存改善相关。
  • 作者认为,在LVAD植入时对显著瓣膜病变行积极外科干预可能对部分患者有益。

研究设计与样本

  • 回顾性单中心研究,纳入2008至2015年接受LVAD(HeartMate II;Abbott,Abbott Park,IL)植入的所有患者。
  • 共270例患者植入LVAD,其中233例术前存在显著瓣膜病变,180例(66.6%)接受合并瓣膜干预(主动脉瓣35例、二尖瓣90例、三尖瓣138例)。
  • 按术毕瓣膜状态分为无显著瓣膜反流组(204例)和残余显著瓣膜反流组(66例)。

主要发现

  • 两组短期结局相似,但无显著瓣膜反流组体外循环时间149分钟长于残余瓣膜反流组132分钟(P=0.038)。
  • 随访期间无显著瓣膜反流组平均肺动脉压24 mm Hg vs 残余瓣膜反流组27 mm Hg(P=0.018),肺血管阻力1.8 Wood单位 vs 2.7 Wood单位(P=0.008),无显著瓣膜反流组较残余瓣膜反流组显著改善。
  • 1年生存率无显著瓣膜反流组72%±3% vs 残余瓣膜反流组55%±6%(log-rank P=0.026);1年无心力衰竭入院生存率无显著瓣膜反流组91%±2% vs 残余瓣膜反流组74%±7%(log-rank P=0.026),无显著瓣膜反流组均显著优于残余瓣膜反流组。
  • 合并瓣膜干预并非院内死亡和并发症的独立预测因素。

关键数值与推荐

  • 术毕无显著瓣膜反流者1年生存率72%±3%,残余显著瓣膜反流者55%±6%(log-rank P=0.026)。
  • 术毕无显著瓣膜反流者1年无心力衰竭入院生存率91%±2%,残余显著瓣膜反流者74%±7%(log-rank P=0.026)。
  • 随访平均肺动脉压无显著瓣膜反流组24 mm Hg vs 残余瓣膜反流组27 mm Hg(P=0.018);肺血管阻力1.8 Wood单位 vs 2.7 Wood单位(P=0.008)。

临床怎么用

  • 作者认为,在LVAD植入时对显著瓣膜病变行积极外科干预可能对部分患者有益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This retrospective single-institutional study investigated the effect of significant valvular regurgitation after left ventricular assist device (LVAD) implantation and the role of concomitant valve surgery during LVAD surgery. METHODS: All patients receiving an LVAD (HeartMate II; Abbott, Abbott Park, IL) during 2008 and 2015 were enrolled. The cohort was divided into two groups based on the valve status at the end of the operation: patients without significant valvular regurgitation (no-VR) and those with significant valvular regurgitation (residual-VR). RESULTS: An LVAD was implanted in 270 patients. Of these, 233 had significant preoperative valve disease(s), and 180 (66.6%) received concomitant valve interventions (35 aortic, 90 mitral, 138 tricuspid). At the completion of the LVAD operation, 204 had no-VR and 66 had residual-VR. Short-term outcomes were similar in two groups, except for longer cardiopulmonary bypass time in the no-VR group (149 minutes) than in the residual-VR group (132 minutes, p = 0.038). During follow-up, mean pulmonary artery pressure (24 mm Hg in no-VR vs 27 mm Hg in residual-VR; p = 0.018) and pulmonary vascular resistance (1.8 Wood units in no-VR vs 2.7 Wood units in residual-VR, p = 0.008) significantly improved in no-VR group compared with the residual-VR group. Survival and heart failure admission-free rates at 1 year were significantly superior in the no-VR group compared with the residual-VR group (1-year survival: 72% ± 3% No-VR vs 55% ± 6% residual-VR; log-rank p = 0.026; admission-free survival: 91% ± 2% no-VR vs 74% ± 7% residual-VR; log-rank p = 0.026). Concomitant valve intervention was not an independent predictor of in-hospital death and morbidity. CONCLUSIONS: Absence of valvular lesion after LVAD implantation was associated with improved midterm hemodynamics and survival in the current study. Aggressive surgical intervention for significant valve disease(s) at the time of LVAD implant may be beneficial to selected patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Tanaka A, Kitahara H, Onsager D, et al. Impact of Residual Valve Disease on Survival After Implantation of Left Ventricular Assist Devices. Ann Thorac Surg. 2018. PMID: 30148976. doi:10.1016/j.athoracsur.2018.06.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。